

Keith Bowering

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2430298/publications.pdf>

Version: 2024-02-01

9
papers

202
citations

1937457

4
h-index

1588896

8
g-index

10
all docs

10
docs citations

10
times ranked

307
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1752-1756.	2.2	1
2	Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2019, 10, 177-188.	1.2	2
3	Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 771-775.	1.2	6
4	Die nächtliche Blutzuckeränderung zu Baseline als Prädiktor des Behandlungseffekts einer Bolus-Intensivierung bei insulinbehandelten Patienten mit Typ 2 Diabetes. , 2019, 14, .		0
5	Response to Comment on Russell-Jones et al. <i>Diabetes Care</i> 2017;40:943-950. Comment on Bowering et al. <i>Diabetes Care</i> 2017;40:951-957. <i>Diabetes Care</i> , 2018, 41, e29-e30.	4.3	2
6	The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis. <i>Diabetic Medicine</i> , 2018, 35, 1273-1278.	1.2	1
7	Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. <i>Diabetes Care</i> , 2017, 40, 951-957.	4.3	102
8	Durability and tolerability of dapagliflozin over 52 weeks as addition to metformin and sulphonylurea in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1075-1084.	2.2	52
9	A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. <i>Diabetic Medicine</i> , 2012, 29, e263-72.	1.2	36